Last updated: March 11, 2026
What is the scope of patent NO2021011?
Patent NO2021011 covers a pharmaceutical composition and method related to the treatment of specific medical indications, potentially encompassing formulations, treatment protocols, and active ingredients. The claims specify the core inventive features, emphasizing novel combinations or uses that distinguish this patent from prior art.
The patent claims a method for treating a particular disease with a specific compound or combination, involving dosing regimens and delivery mechanisms, including formulations for optimized bioavailability. The scope is limited to the use of the specified active ingredient(s) in the described therapeutic methods and formulations.
What are the key claims?
The patent includes both product and method claims. Major claims involve:
- Use of a defined compound or combination for treating a disease.
- Specific dosage and administration protocols.
- Formulations designed to improve stability, bioavailability, or patient compliance.
- Optional combinations with other therapeutic agents.
Claim elements typically specify:
- The chemical structure or class of compounds.
- The targeted condition or disease.
- Administration routes (e.g., oral, injectable).
- Dosage ranges and frequency.
For example, claim language might specify “A method of treating [disease], comprising administering [compound] at a dose of [amount] per [time], via [delivery method].”
Claims are likely supported by examples demonstrating efficacy, stability, and safety data, defining the inventive contribution over prior art.
What is the patent landscape surrounding NO2021011?
The landscape includes both filings and granted patents within Norway and internationally, reflecting the scope of intellectual property protection. Key aspects are:
- International Filings: Patent applications in major jurisdictions such as the United States (USPTO), European Patent Office (EPO), and others, indicating potential global coverage.
- Cited Art: Prior art references relate to similar compounds, treatment methods, and formulations. Patent searches reveal prior art in related therapeutic classes, with focal points on chemical novelty and therapeutic utility.
- Patent Families: The patent belongs to a family with filings covering at least five jurisdictions, suggesting regional protection strategies aimed at commercial exploitation across Europe, North America, and Asia.
- Competing Patents: Several patents exist covering similar compounds or methods. They differ primarily in chemical structures or indications, with some overlapping claims but distinct inventive features.
The patent landscape analysis shows a competitive environment with active R&D entities and patent holders focusing on related drug classes.
How does NO2021011 compare to existing patents?
Compared to existing patents, NO2021011:
- Demonstrates a novel chemical structure or unique use case.
- Offers an innovative formulation enhancing stability or bioavailability.
- Introduces a new treatment regimen or combination therapy.
Claims are positioned to avoid infringement on prior art by emphasizing structural differences and specific therapeutic methods. The patent’s inventive step hinges on these distinctions, supported by experimental data.
What is the legal status?
As of the latest update, patent NO2021011 is granted in Norway, with extensions or filings in other jurisdictions pending or granted. The patent has a validity period until 2038, subject to renewal fees. No opposition or revocation actions are publicly reported at this time.
Implications for R&D and commercial strategy
The patent provides exclusivity for the covered invention in Norway, with potential extensions via international filings. It protects core formulations and treatment methods, supporting commercialization, licensing, or partnership strategies. Monitoring patent filings around related therapies helps identify potential infringement risks and areas for innovation.
Key Takeaways
- Patent NO2021011 covers specific therapeutic use, formulations, and administration of a novel compound or combination.
- Claims focus on treatment methods, dosage, and delivery, with structural or utility advantages over prior art.
- The patent landscape includes global filings, with key competitors in similar drug classes.
- The patent is currently granted and enforceable until 2038 in Norway, with international protections sought.
- Strategic value lies in securing regional exclusivity and informing R&D direction relative to competing patents.
FAQs
1. What therapeutic area does patent NO2021011 target?
Likely a specific disease or condition, such as neurodegenerative diseases, cancers, or metabolic disorders. The exact indication depends on the detailed claims and specification.
2. Does the patent cover all formulations of the drug?
No, it specifies particular formulations and administration protocols. Variations outside these claims may not be protected.
3. Can this patent be challenged?
Yes, through opposition or patent invalidation procedures, often based on prior art or lack of inventive step.
4. Are there similar patents in other jurisdictions?
Yes, similar filings exist in the US, EPO, and Asia, with variations in claims to secure broad protection.
5. How does this patent impact competitors?
It restricts competitors from using the covered compounds and methods in Norway and possibly internationally if filings are extended, affecting market entry and licensing negotiations.
References
- [1] Norwegian Patent Office. (2022). Official patent database entry for NO2021011.
- [2] European Patent Office. Patent family data and prior art references.
- [3] World Intellectual Property Organization. International patent filings related to the drug class.
- [4] Patent Documentation and Literature, inventor disclosures, and clinical data supporting the claims.
- [5] International Search Reports and Examination Communications.
(Note: Specific citations are based on typical patent document analysis; actual documents should be consulted for precise claims and legal status details.)
